Functional factor XIII-A is exposed on the stimulated platelet surface

Blood

Volumn 124, Issue 26, 2014, Pages 3982-3990

  Mitchell, Joanne L ^a   Lionikiene, Ausra S ^a   Fraser, Steven R ^a   Whyte, Claire S ^a   Booth, Nuala A ^a   Mutch, Nicola J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13A; COLLAGEN; FIBRIN; NEUTRALIZING ANTIBODY; PHOSPHATIDYLSERINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; THROMBIN; ANTIFIBRINOLYTIC AGENT; CROSS LINKING REAGENT;

ARTICLE; BLOOD CLOT LYSIS; CELL FRACTIONATION; CELL STIMULATION; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEMBRANE STABILIZATION; PROTEIN CROSS LINKING; PROTEIN DEPLETION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBUS; BLOOD CLOTTING; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; FIBRINOLYSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOSIS;

ALPHA-2-ANTIPLASMIN; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD PLATELETS; CELL MEMBRANE; COLLAGEN; CROSS-LINKING REAGENTS; CYTOPLASM; FACTOR XIIIA; FIBRIN; FIBRINOLYSIS; FLOW CYTOMETRY; HUMANS; MICROSCOPY, CONFOCAL; PLATELET ACTIVATION; THROMBIN; THROMBOSIS; TRANSGLUTAMINASES;

EID: 84919476363     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-583070     Document Type: Article

References (75)

1. 2-antiplasmin cross-linking. Blood. 2011;117(23):6371-6374.
2. Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem. 1994;269(45):28414-28419.
3. Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest. 1982;69(3):536-542.
4. Fisher S, Rikover M, Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood. 1966;28(1):34-39.
5. Dardik R, Solomon A, Loscalzo J, et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol. 2003;23(8):1472-1477.
6. Aziz MA, Siddigui AR. Congenital deficiency of fibrin-stabilizing factor (factor XIII): a report of four cases (two families) and family members. Blood. 1972;40(1):11-15.
7. Losowsky MS, Hall R, Goldie W. Congenital deficiency of fibrin-stabilising factor; a report of three unrelated cases. Lancet. 1965;1(7404):156-158.
8. Katona E, Pénzes K, Csapó A, et al. Interaction of factor XIII subunits. Blood. 2014;123(11):1757-1763.
9. Lorand L, Konishi K. Activation of the Fibrin Stabilizing Factor of Plasma by Thrombin. Arch Biochem Biophys. 1964;105:58-67.
10. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973;248(4):1395-1407.
11. Mockros LF, Roberts WW, Lorand L. Viscoelastic properties of ligation-inhibited fibrin clots. Biophys Chem. 1974;2(2):164-169.
12. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest. 1983;71(5):1336-1341.
13. Pisano JJ, Finlayson JS, Peyton MP. [Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine]. Science. 1968;160(3830):892-893.
14. Pisano JJ, Finlayson JS, Peyton MP. Chemical and enzymic detection of protein cross-links. Measurement of epsilon-(gamma-glutamyl)lysine in fibrin polymerized by factor XIII. Biochemistry. 1969;8(3):871-876.
15. Gladner JA, Nossal R. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res. 1983;30(3):273-288.
16. McKee PA, Mattock P, Hill RL. Subunit structure of human fibrinogen, soluble fibrin, and crosslinked insoluble fibrin. Proc Natl Acad Sci USA. 1970;66(3):738-744.
17. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980;65(2):290-297.
18. Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 1998;273(42):27220-27224.
19. Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb Haemost. 1999;81(1):96-103.
20. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976;251(19):5956-5965.
21. Ichinose A, Mimuro J, Koide T, Aoki N. Histidinerich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. Thromb Res. 1984;33(4):401-407.
22. Kimura S, Aoki N. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem. 1986;261(33):15591-15595.
23. Lopaciuk S, Lovette KM, McDonagh J, Chuang HY, McDonagh RP. Subcellular distribution of fibrinogen and factor XIII in human blood platelets. Thromb Res. 1976;8(4):453-465.
24. Sixma JJ, van den Berg A, Schiphorst M, Geuze HJ, McDonagh J. Immunocytochemical localization of albumin and factor XIII in thin cryo sections of human blood platelets. Thromb Haemost. 1984;51(3):388-391.
25. Nurden AT, Kunicki TJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood. 1982;59(4):709-718.
26. Zhu Y, Tassi L, Lane W, Mendelsohn ME. Specific binding of the transglutaminase, platelet factor XIII, to HSP27. J Biol Chem. 1994;269(35):22379-22384.
27. Schwartz ML, Pizzo SV, Hill RL, McKee PA. The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem. 1971;246(18):5851-5854.
28. Katona E E, Ajzner E, Tóth K, Kárpáti L, Muszbek L. Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Methods. 2001;258(1-2):127-135.
29. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94(5):271-305.
30. Muszbek L, Ariëns RA, Ichinose A; ISTH SSC SUBCOMMITTEE ON FACTOR XIII. Factor XIII: recommended terms and abbreviations. J Thromb Haemost. 2007;5(1):181-183.
31. Muszbek L, Polgár J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost. 1993;69(3):282-285.
32. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79(4):920-928.
33. Reed GL, Matsueda GR, Haber E. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis. Trans Assoc Am Physicians. 1991;104:21-28.
34. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost. 1992;68(3):315-320.
35. Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Thromb Haemost. 1996;75(1):161-167.
36. Francis CW, Marder VJ. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest. 1987; 80(5):1459-1465.
37. Joist JH, Niewiarowski S. Retention of platelet fibrin stabilizing factor during the platelet release reaction and clot retraction. Thromb Diath Haemorrh. 1973;29(3):679-683.
38. Cordell PA, Kile BT, Standeven KF, Josefsson EC, Pease RJ, Grant PJ. Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion. Blood. 2010;115(13):2674-2681.
39. Mutch NJ, Koikkalainen JS, Fraser SR, et al. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost. 2010;8(9):2017-2024.
40. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70(3):327-333.
41. Baeten KM, Richard MC, Kanse SM, Mutch NJ, Degen JL, Booth NA. Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. J Thromb Haemost. 2010;8(6):1313-1322.
42. Raut S, Merton RE, Rigsby P, et al; ISTH/SSC Factor XIII Subcommittee and the Factor XIII Standardization Working Party. A collaborative study to establish the 1st International Standard for factor XIII plasma. J Thromb Haemost. 2007;5(9):1923-1929.
43. Freund KF, Doshi KP, Gaul SL, et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry. 1994;33(33):10109-10119.
44. Jayo A, Conde I, Lastres P, Jiménez-Yuste V, González-Manchón C. New insights into the expression and role of platelet factor XIII-A. J Thromb Haemost. 2009;7(7):1184-1191.
45. McDonagh J, McDonagh RP Jr, Delâge JM, Wagner RH. Factor XIII in human plasma and platelets. J Clin Invest. 1969;48(5):940-946.
46. Kreager JA, Devine DV, Greenberg CS. Cytofluorometric identification of plasmin-sensitive factor XIIIa binding to platelets. Thromb Haemost. 1988;60(1):88-93.
47. Nagy B Jr, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost. 2009;102(1):83-89.
48. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90(7):2615-2625.
49. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95(5):1694-1702.
50. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
51. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179.
52. Jobe SM, Leo L, Eastvold JS, et al. Role of FcRgamma and factor XIIIA in coated platelet formation. Blood. 2005;106(13):4146-4151.
53. Abaeva AA, Canault M, Kotova YN, et al. Procoagulant platelets form an α-granule protein-covered "cap" on their surface that promotes their attachment to aggregates. J Biol Chem. 2013;288(41):29621-29632.
54. Marx G, Korner G, Mou X, Gorodetsky R. Packaging zinc, fibrinogen, and factor XIII in platelet alpha-granules. J Cell Physiol. 1993;156(3):437-442.
55. Kreutz RP, Owens J, Lu D, et al. Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel [published online ahead of print May 15, 2014]. Platelets. doi: 10.3109/09537104.2014.916793.
56. Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation. 2000;102(10):1151-1157.
57. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood. 1988;71(5):1361-1365.
58. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost. 2007;5(4):812-817.
59. Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-aIIbb3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood. 2013;122(19):3340-3348.
60. Maroney SA, Haberichter SL, Friese P, et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood. 2007;109(5):1931-1937.
61. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94(11):3791-3799.
62. Holme PA, Brosstad F, Solum NO. The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation. Thromb Haemost. 1993;70(4):681-686.
63. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002;90(4):428-434.
64. Collet JP, Montalescot G, Lesty C, et al. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001;103(19):2328-2331.
65. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol. 2001;21(1):142-148.
66. Shenkman B, Einav Y, Livnat T, Budnik I, Martinowitz U. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. Blood Transfus. 2014;12(1):78-84.
67. Letheby BA, Davis RB, Larsen AE. The effect of major surgical procedures on plasma and platelet levels of Factor XIII. Thromb Diath Haemorrh. 1974;31(1):20-29.
68. Janning M, Holstein K, Spath B, et al. Relevant bleeding diathesis due to acquired factor XIII deficiency. Hamostaseologie. 2013;33(Suppl 1):S50-S54.
69. Saito M, Asakura H, Yoshida T, et al. A familial factor XIII subunit B deficiency. Br J Haematol. 1990;74(3):290-294.
70. Izumi T, Hashiguchi T, Castaman G, et al. Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood. 1996;87(7):2769-2774.
71. Koseki S, Souri M, Koga S, et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood. 2001;97(9):2667-2672.
72. Ajzner E, Schlammadinger A, Kerényi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood. 2009;113(3):723-725.
73. Souri M, Koseki-Kuno S, Takeda N, Degen JL, Ichinose A. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol. 2008;87(1):60-68.
74. Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. Arteriosclerosis. 1990;10(1):49-61.
75. Tijburg PN, Ijsseldijk MJ, Sixma JJ, de Groot PG. Quantification of fibrin deposition in flowing blood with peroxidase-labeled fibrinogen. High shear rates induce decreased fibrin deposition and appearance of fibrin monomers. Arterioscler Thromb. 1991;11(2):211-220.